Nasic (Mometasone Furoate Monohydrate)

Mometasone furoate monohydrate binds to glucocorticoid receptors in the nasal mucosa, inhibiting the release of inflammatory mediators such as cytokines and prostaglandins. This anti‑inflammatory action reduces swelling and mucus production, improving nasal airflow.

The prescribed dose of Nasic is determined by the treating clinician. Typically, one or two sprays per nostril once daily are used, but the exact regimen should follow the healthcare professional’s instructions.

Safety of Nasic during pregnancy or lactation has not been definitively established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and always under medical supervision.

To order Nasic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasic (mometasone furoate) offers a high receptor affinity and a low systemic bioavailability, similar to other potent nasal steroids such as fluticasone propionate and budesonide. Clinical studies suggest comparable efficacy in symptom control, with a favorable safety profile when used as directed.

Store Nasic at room temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Before first use, prime the spray by pressing the actuator several times until a fine mist appears. Tilt the head slightly forward, insert the tip into a nostril, and gently squeeze one spray while breathing in through the nose. Repeat in the other nostril if prescribed.

Serious risks include nasal septum perforation, opportunistic fungal infections of the nasal passages, severe or persistent nosebleeds, and, with prolonged high‑dose use, possible adrenal suppression. Any unusual symptoms should be reported to a healthcare professional promptly.

Nasic should be avoided in individuals with known hypersensitivity to mometasone or any component of the formulation, those with recent nasal surgery or trauma, and patients with active untreated nasal infections. Consultation with a clinician is essential before starting therapy.